Keyword: Esmya (ulipristal)
In light of increased antitrust scrutiny over pharma M&A, AbbVie will also cut a few products to win U.S. clearance for its Allergan buyout.
AbbVie’s first campaign for Orilissa is a play on the brand name for the endometriosis pain drug.
Allergan aims to sell its women’s health unit, but Esmya's FDA rejection will take a big bite out of its price.
Billionaire David Tepper has permission to make an activist run at Allergan. Will he use it—and if so, how?
With the EMA investigating Esmya for liver safety, the FDA told Allergan on Wednesday that it would need some more time to examine its application for the product.
The EMA has been probing the safety of Allergan’s Esmya since December. Now it's advising no new patients start taking it until the investigation wraps up.
AbbVie’s new awareness campaign Speak Endo centers on the "hammering" and "stabbing" pains that come with endometriosis.
As Allergan chases a U.S. approval for uterine fibroids drug Esmya, across the pond, regulators are investigating the treatment for liver damage.
Allergan thinks uterine fibroid treatment Esmya could become a flagship product. But the company knows that getting it there won’t be easy—or cheap.
Pharma's big on disease awareness, but Allergan is going really big with its latest push: It’s aiming for a whole month dedicated to uterine fibroids.